CLIN-IMMUNOTHERAPY/BIOLOGIC THERAPIES
Ian F. Pollack(Children's Hospital of Pittsburgh), Frank S. Lieberman(University of Pittsburgh), Ian D. Schnadig, Akihiro Tsuboi, Hiroaki Sugiyama(Osaka University), Nobuyuki Hashimoto(Osaka Gakuin University), Javier Aristu(Memorial Sloan Kettering Cancer Center), Mark O. Lively(Wake Forest University), Lisa H. Butterfield(Merck & Co., Inc., Rahway, NJ, USA (United States)), Yoshiyuki Chiba(Boston Children's Hospital), Maurizio Bendandi(Universidad de Navarra), Junjie Zhu(Boston Children's Hospital), Susana Inogés(Universidad de Navarra), Sonia Tejada(Universidad de Navarra), Haitao Fan(Ningbo University), Amy M. Salazar, Yusuke Oji(The University of Osaka), E. Yu, H. Wang(Shandong University), X. Chen(Shandong University), L. Zhang(City Of Hope National Medical Center), Ryuichi Hirayama(The University of Osaka), C. Chen, Michael D. Chan(Wake Forest University), Johnathan A. Engh(University of Pittsburgh), Hideho Okada(University of California, San Francisco), Noriyuki Kijima(The University of Osaka), I. Zhang(City Of Hope National Medical Center), J. Espinós(Universidad de Navarra), Rahul Dhanda, José Palacios Calvo(Universidad de Navarra), Manabu Kinoshita(Brigham and Women's Hospital), Behnam Badie(City Of Hope National Medical Center), Miguel Á. Idoate(Universidad de Navarra), Arliene Ravelo(Dana-Farber Cancer Institute), Jan Drappatz(University of Pittsburgh), Edward G. Shaw(Wake Forest University), Toshiki Yoshimine(Kishokai Medical Corporation), Regina I. Jakacki(Boston Children's Hospital), Arlan Mintz(University of Pittsburgh), N. Kagawa(The University of Osaka), Y. Oka, Hiroyuki Okada(University of Pittsburgh), Anna Da Fonseca(Universidade Federal do Rio de Janeiro), D. Potter(University of Pittsburgh), Ascensión López-Díaz De Cerio(Chartered Institute of Management Accountants), Ronald L. Hamilton(University of Pittsburgh), J. Gállego(Universidad de Navarra), Ricardo Díez Valle(Hospital Universitario Fundación Jiménez Díaz)
Cited by 1
Related Papers
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
|New England Journal of Medicine|2016|1.8k
Intertumoral Heterogeneity within Medulloblastoma Subgroups
|Cancer Cell|2017|1.3k
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial
|The Lancet Oncology|2017|1.1k
Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma
|New England Journal of Medicine|2016|1k
Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma
|Clinical Cancer Research|2015|754